Premium
Treatment with anti‐ OX 40L or anti‐ TSLP does not alter the frequency of T regulatory cells in allergic asthmatics
Author(s) -
Baatjes A. J.,
Smith S. G.,
Dua B.,
Watson R.,
Gauvreau G. M.,
O'Byrne P. M.
Publication year - 2015
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.12708
Subject(s) - thymic stromal lymphopoietin , foxp3 , immunology , medicine , treg cell , monoclonal antibody , regulatory t cell , asthma , flow cytometry , il 2 receptor , antibody , immune system , t cell
Abstract OX 40‐ OX 40L interactions and thymic stromal lymphopoietin ( TSLP ) are important in the induction and maintenance of Th2 responses in allergic disease, whereas T regulatory cells (Treg) have been shown to suppress pro‐inflammatory Th2 responses. Both OX 40L and TSLP have been implicated in the negative regulation of Treg. The effect of anti‐asthma therapies on Treg is not well known. Our aim was to assess the effects of two monoclonal antibody therapies (anti‐ OX 40L and anti‐ TSLP ) on Treg frequency using a human model of allergic asthma. We hypothesized that the anti‐inflammatory effects of these therapies would result in an increase in circulating Treg ( CD 4 + CD 25 + CD 127 low Foxp3 + cells) frequency. We measured Treg using flow cytometry, and our results showed that neither allergen challenge nor monoclonal antibody therapy altered circulating Treg frequency. These data highlight the need for assessment of airway Treg and for a more complete understanding of Treg biology so as to develop pharmacologics/biologics that modulate Treg for asthma therapy.